texas oncology more breakthroughs. more victories

Baylor Charles A. Sammons Research & Clinical Trials

Baylor Charles A. Sammons Cancer Center participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Innovative Clinical Trial Center (Expand)

Biliary Cancer

STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements Read Moreabout STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

Phase: II

Breast Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Endometrial Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Head and Neck Cancer

STAR Ph3 study to evaluate to treat patients with HNSCC

A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02) Read Moreabout STAR Ph3 study to evaluate to treat patients with HNSCC

Phase: III

Lung Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217) Read Moreabout STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

Phase: III

Ovarian Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Solid Tumors

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01) Read Moreabout STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Phase: IV

Texas Oncology-Baylor Charles A. Sammons Cancer Center (Expand)

Anemia

A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Phase: III

Biliary Cancer

STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308)

A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308) Read Moreabout STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308)

Phase: III

Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01)

A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001) Read Moreabout Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01)

Phase: III

Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC)

An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302) Read Moreabout Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC)

Phase: III

STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements Read Moreabout STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

Phase: II

Breast Cancer

Ph2 ARX788 HER2 BC T-DMI T-DXd

A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03) Read Moreabout Ph2 ARX788 HER2 BC T-DMI T-DXd

Phase: II

A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Phase: I/II

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE)

A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222) Read Moreabout Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE)

Phase: I/II

Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer

A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201) Read Moreabout Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer

Phase: II

Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

Phase: III

Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002) Read Moreabout Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

Phase: III

ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer

A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303) Read Moreabout ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer

Phase: III

Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)

A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001) Read Moreabout Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)

Phase: III

Ph2 clinical trial of BNT327 in combo with treatment in breast cancer

A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02) Read Moreabout Ph2 clinical trial of BNT327 in combo with treatment in breast cancer

Phase: II

Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)

A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001) Read Moreabout Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)

Phase: III

Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)

A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001) Read Moreabout Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)

Phase: III

Ph3 GDC-9545 ER+ HER2- BC (lidERA)

A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784) Read Moreabout Ph3 GDC-9545 ER+ HER2- BC (lidERA)

Phase: III

Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast

A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657) Read Moreabout Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast

Phase: III

Ph3 HER2/neu BC (FLAMINGO-01)

A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)

Phase: III

Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer

An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010) Read Moreabout Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer

Phase: II

Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001) Read Moreabout Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer

Phase: I

Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase: III

Ph3 study of standard endocrine therapy with breast cancer

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422) Read Moreabout Ph3 study of standard endocrine therapy with breast cancer

Phase: III

Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

Phase: III

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Ryz101 for SSTR+ ER+HER2 metastatic breast cancer

Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201) Read Moreabout Ryz101 for SSTR+ ER+HER2 metastatic breast cancer

Phase: I/II

SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC

Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381) Read Moreabout SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC

Phase: II

Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Phase: III

Cervical Cancer

Ph3 robotic Hysterectomy ROCC

(GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial) Read Moreabout Ph3 robotic Hysterectomy ROCC

Phase: III

Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01) Read Moreabout Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

Phase: I/II

GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer

A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00) Read Moreabout GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer

Phase: III

Colon Cancer

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001) Read Moreabout Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

Phase: I/II

Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

Phase: I

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002) Read Moreabout Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

Phase: III

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01) Read Moreabout Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC

Phase: I/II

Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

Phase: III

Endometrial Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II

Ph3 Selin P53 Endo Carcinoma

A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042) Read Moreabout Ph3 Selin P53 Endo Carcinoma

Phase: III

Ph3 study of GOG-3104 with endometrial cancer

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769) Read Moreabout Ph3 study of GOG-3104 with endometrial cancer

Phase: III

Esophageal Cancer

Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001) Read Moreabout Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

Phase: I

Fallopian Tube Cancer

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Gastric Cancer

Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001) Read Moreabout Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

Phase: I

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Phase: II

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Graft vs Host Disease

A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD)

A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757) Read Moreabout Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD)

Phase: III

Head and Neck Cancer

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Phase: II

STAR Ph3 study to evaluate to treat patients with HNSCC

A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02) Read Moreabout STAR Ph3 study to evaluate to treat patients with HNSCC

Phase: III

Ph3 study of pembro in HNSCC in the disease without curative therapy available

A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03) Read Moreabout Ph3 study of pembro in HNSCC in the disease without curative therapy available

Phase: III

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Leukemia

A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Phase: I

Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060)

Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032) Read Moreabout Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060)

Phase: II

Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008) Read Moreabout Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML

Phase: I

Liver Cancer

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460)

A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719) Read Moreabout Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460)

Phase: II

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Lung Cancer

Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3)

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005) Read Moreabout Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3)

Phase: I/II

Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001) Read Moreabout Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

Phase: I/II

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

Phase: I/II

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC

A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153) Read Moreabout Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC

Phase: II

Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201) Read Moreabout Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

Phase: II

Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005) Read Moreabout Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

Phase: II

Ph2 MRTX849 Pembro NSCLC KRAS

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout Ph2 MRTX849 Pembro NSCLC KRAS

Phase: II/III

Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17)

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017) Read Moreabout Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17)

Phase: II

Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)

A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012) Read Moreabout Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)

Phase: II

Ph3 Tarlatamab in combo with Durvalumab ES-SCLC

A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041) Read Moreabout Ph3 Tarlatamab in combo with Durvalumab ES-SCLC

Phase: III

STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217) Read Moreabout STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

Phase: III

A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Phase: III

Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)

A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001) Read Moreabout Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)

Phase: III

A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Phase: IIIB

Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003) Read Moreabout Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

Phase: III

Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)

A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007) Read Moreabout Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)

Phase: III

Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4)

A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721) Read Moreabout Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4)

Phase: II/III

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Phase: II

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Phase: III

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) Read Moreabout ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase: III

Lymphomas

Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

Phase: I

Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma

A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003) Read Moreabout Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma

Phase: III

Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma

A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145) Read Moreabout Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma

Phase: III

Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3)

A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202] Read Moreabout Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3)

Phase: II

Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Phase: I

Melanoma

Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122) Read Moreabout Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma

Phase: III

A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Phase: II

Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2

A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02) Read Moreabout Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2

Phase: III

Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002) Read Moreabout Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2

Phase: II/III

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Multiple

PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Myelofibrosis

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER-103)

Phase: I

A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Phase: I/III

Myelomas

Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM

A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022) Read Moreabout Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM

Phase: III

Ovarian Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6)

A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002) Read Moreabout Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6)

Phase: II

Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)

A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301) Read Moreabout Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)

Phase: III

Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer

A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02) Read Moreabout Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer

Phase: III

Pancreatic Cancer

Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001) Read Moreabout Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

Phase: I

Ph1/2 FIH MRTX1719 ST MTAP Deletion

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007) Read Moreabout Ph1/2 FIH MRTX1719 ST MTAP Deletion

Phase: I/II

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)

A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302) Read Moreabout Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)

Phase: III

Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Phase: III

Peritoneal Cancer

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Prostate Cancer

Ph3 study of MK-5684 versus alternative NHA in mCRPC

A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004) Read Moreabout Ph3 study of MK-5684 versus alternative NHA in mCRPC

Phase: III

Rectal Cancer

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

Phase: I

Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002) Read Moreabout Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

Phase: III

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01) Read Moreabout Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC

Phase: I/II

Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

Phase: III

Renal Cancer

Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC

A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030) Read Moreabout Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC

Phase: I

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Solid Tumors

A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Phase: I/II

Ph1/2 FIH MRTX1719 ST MTAP Deletion

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007) Read Moreabout Ph1/2 FIH MRTX1719 ST MTAP Deletion

Phase: I/II

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Phase: I

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001) Read Moreabout Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

Phase: I/II

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01) Read Moreabout Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

Phase: I/II

A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Phase: II

STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors

A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001) Read Moreabout STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors

Phase: I/II

STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01) Read Moreabout STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Phase: IV

First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Phase: I

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001) Read Moreabout Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase: I/II

Thrombocytopenia

A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Phase: III

Urothelial Cancer

Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01) Read Moreabout Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

Phase: I/II

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Uterine Cancer

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II